Zentalis Pharmaceuticals Inc (ZNTL)

$1.42 -0.03 (-2.07%)
Market Cap 107.48M
Revenue (ttm) 67.43M
Net Income (ttm) -165.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -245.94%
Debt to Equity Ratio 0.00
Volume 610,600
Avg Vol 755,584
Day's Range N/A - N/A
Shares Out 72.14M
Stochastic %K 8%
Beta 1.76
Analysts Sell
Price Target $5.74

Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 433 3791
Address:
10275 Science Center Dr., Suite 200, San Diego, United States
Snackdaddy
Snackdaddy Sep. 15 at 3:11 PM
$ZNTL come to me $1.30S
1 · Reply
Biotechnicity
Biotechnicity Sep. 12 at 8:39 PM
$ZNTL over $1.80 a blink back. Now, 2-cents from my entry price. That’s biotech!
1 · Reply
Gaben
Gaben Sep. 12 at 5:57 PM
$ZNTL No one sees any value in this company anymore! The share price is slowly reaching a new low.
1 · Reply
Shad0ws
Shad0ws Sep. 11 at 2:37 PM
$ZNTL just added over 40k . Matter of time here
1 · Reply
highnihilism
highnihilism Sep. 11 at 1:01 PM
$ZNTL Zentalis Pharmaceuticals dosed first patient in the DENALI Part 2 trial of azenosertib. Completed a strategic restructuring earlier in 2025 to fund late-stage development. #SG Sweetgreen’s luxury athleisure lifestyle setting: bright & clean interior, crisp greens, bright wooden textures (post-class vibe) is reinforcing the $18 level. Where energized femininity resonates. #XHB Homebuilder demand trends & housing supply dynamics are reinforcing the $128 level. Fed rate-cut speculation & “golden cross” approaching. #BTC Bitcoin’s on-chain metrics & institutional flows are propping up the $114,000 level. Fed rate-cut speculation & “liquidity expansion.”
0 · Reply
Snackdaddy
Snackdaddy Sep. 10 at 7:28 PM
$ZNTL guess there silly fireside chats did nothing for investors. broke $1.50 back to $1.30S from a month ago?
1 · Reply
Snackdaddy
Snackdaddy Sep. 10 at 5:56 PM
$ZNTL we have bleeder!
0 · Reply
Sillyspuh
Sillyspuh Sep. 8 at 3:22 PM
$ZNTL This FDA should love a non-chemo, oral option for Ovarian cancer.
2 · Reply
VM0007
VM0007 Sep. 8 at 2:17 PM
$ZNTL Read Page 7 of the August corporate presentation. Abbvie (trading at 7x Sales) is selling about $700M of a similar drug to Azeno (though focused on a different biomarker). Azeno has a potential of 1.5x the Abbvie's drug. Sadly, ZNTL is trading at less than 0.5x cash (!).
1 · Reply
Sillyspuh
Sillyspuh Sep. 4 at 6:54 PM
$ZNTL Really strong presentation from Julie and Ingmar today at the Wells Fargo healthcare conference. If they keep doing these, investors will get on board.
1 · Reply
Latest News on ZNTL
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:27 PM EDT - 7 days ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 2, 2025, 5:00 PM EDT - 14 days ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 28, 2025, 4:15 PM EDT - 19 days ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Aug 26, 2025, 4:05 PM EDT - 21 days ago

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Aug 6, 2025, 4:05 PM EDT - 5 weeks ago

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 5:00 PM EDT - 2 months ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025, 4:05 PM EDT - 4 months ago

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Apr 28, 2025, 8:00 AM EDT - 5 months ago

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Apr 23, 2025, 4:05 PM EDT - 5 months ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Mar 26, 2025, 4:05 PM EDT - 6 months ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 25, 2025, 4:40 PM EDT - 6 months ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 15, 2025, 11:25 AM EDT - 6 months ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 3, 2025, 8:00 AM EST - 7 months ago

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Jan 29, 2025, 7:00 AM EST - 8 months ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Jan 28, 2025, 4:05 PM EST - 8 months ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Jan 9, 2025, 7:00 AM EST - 8 months ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Zentalis Pharmaceuticals Announces Key Management Appointments

Dec 12, 2024, 7:00 AM EST - 9 months ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Nov 21, 2024, 1:14 PM EST - 10 months ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Sep 16, 2024, 9:00 AM EDT - 1 year ago

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Aug 19, 2024, 4:55 PM EDT - 1 year ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 15, 2024, 4:00 PM EDT - 1 year ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 12, 2024, 11:15 PM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Snackdaddy
Snackdaddy Sep. 15 at 3:11 PM
$ZNTL come to me $1.30S
1 · Reply
Biotechnicity
Biotechnicity Sep. 12 at 8:39 PM
$ZNTL over $1.80 a blink back. Now, 2-cents from my entry price. That’s biotech!
1 · Reply
Gaben
Gaben Sep. 12 at 5:57 PM
$ZNTL No one sees any value in this company anymore! The share price is slowly reaching a new low.
1 · Reply
Shad0ws
Shad0ws Sep. 11 at 2:37 PM
$ZNTL just added over 40k . Matter of time here
1 · Reply
highnihilism
highnihilism Sep. 11 at 1:01 PM
$ZNTL Zentalis Pharmaceuticals dosed first patient in the DENALI Part 2 trial of azenosertib. Completed a strategic restructuring earlier in 2025 to fund late-stage development. #SG Sweetgreen’s luxury athleisure lifestyle setting: bright & clean interior, crisp greens, bright wooden textures (post-class vibe) is reinforcing the $18 level. Where energized femininity resonates. #XHB Homebuilder demand trends & housing supply dynamics are reinforcing the $128 level. Fed rate-cut speculation & “golden cross” approaching. #BTC Bitcoin’s on-chain metrics & institutional flows are propping up the $114,000 level. Fed rate-cut speculation & “liquidity expansion.”
0 · Reply
Snackdaddy
Snackdaddy Sep. 10 at 7:28 PM
$ZNTL guess there silly fireside chats did nothing for investors. broke $1.50 back to $1.30S from a month ago?
1 · Reply
Snackdaddy
Snackdaddy Sep. 10 at 5:56 PM
$ZNTL we have bleeder!
0 · Reply
Sillyspuh
Sillyspuh Sep. 8 at 3:22 PM
$ZNTL This FDA should love a non-chemo, oral option for Ovarian cancer.
2 · Reply
VM0007
VM0007 Sep. 8 at 2:17 PM
$ZNTL Read Page 7 of the August corporate presentation. Abbvie (trading at 7x Sales) is selling about $700M of a similar drug to Azeno (though focused on a different biomarker). Azeno has a potential of 1.5x the Abbvie's drug. Sadly, ZNTL is trading at less than 0.5x cash (!).
1 · Reply
Sillyspuh
Sillyspuh Sep. 4 at 6:54 PM
$ZNTL Really strong presentation from Julie and Ingmar today at the Wells Fargo healthcare conference. If they keep doing these, investors will get on board.
1 · Reply
Snackdaddy
Snackdaddy Sep. 4 at 6:03 PM
$ZNTL somebody devoured that dip
0 · Reply
Biotechnicity
Biotechnicity Aug. 27 at 2:29 PM
$ZNTL is up over 60% in the last 2-months. TWO
2 · Reply
Biotechnicity
Biotechnicity Aug. 25 at 7:50 PM
$ZNTL so, it appears the hedgies took their usual Friday off last week and Monday they’re back.
1 · Reply
StockScanners
StockScanners Aug. 23 at 6:45 PM
$ZNTL reached 2.05, not bad, lets find another together
0 · Reply
Biotechnicity
Biotechnicity Aug. 22 at 3:12 PM
$ZNTL we be crushing it
0 · Reply
lucabrix
lucabrix Aug. 22 at 2:56 PM
$ZNTL run baby run!
0 · Reply
StockScanners
StockScanners Aug. 22 at 5:50 AM
$ZNTL keep watch if this holds above 1.75
0 · Reply
Biotechnicity
Biotechnicity Aug. 22 at 2:10 AM
$ZNTL is up 46% in the last month and a half alone. This will run to 5 easy over the next 18 months. Buy the dips. Admire the mounds.
0 · Reply
Rafael_
Rafael_ Aug. 21 at 6:01 PM
$ZNTL Huge Cash loss every quarter. Data comes out late(2026 Q4) which means no catalyst for a whole year Avoid.
1 · Reply
InstinctInvestor
InstinctInvestor Aug. 21 at 5:35 PM
TOP swings $ZNTL $THAR $IMRX IM LOOKING TO PLAY
0 · Reply
cassis26
cassis26 Aug. 21 at 5:15 PM
$ZNTL I’m curious as to everyone’s thoughts. Trades at a severely depressed valuation, $1.80 now with north of $4 cash on hand. Phase 2 drug with clear path to registration. With 300 mil cash on hand dilution risk seems minimal. And then some fascinating players in the game. Billy Walter’s with a 9.9% stake. He did well with Zogenix. Jan Skvarka on the board- Trils prior CEO who negotiated the Pfizer buyout. Julie Eastland from Harpoons buyout. Ingmar Bruns - Trils CMO and then big hem/onc player at Pfizer. Scott Myers. Brought in just before the Tril buyout. His LinkedIn reads like a closer brought in to sell. Looks to me like all the executives got golden parachutes. Factor in mirvetuximab’s $10 bil valuation in PROC. If Denali shows an ORR > 30% with MDOR over 6 months. I see this drug being valued at $20-30 easily. Then we’ve got a combo study with Enhertu. If this can be paired with ADC’s I could see Pfizer being very interested after their Seagen ADC portfolio acquisition.
2 · Reply
lucabrix
lucabrix Aug. 21 at 2:53 PM
$ZNTL Reply!
0 · Reply